StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The significant drop of 35.7% indicates severe investor concern. Past declines often correlate with poor trial data outcomes.
What happened, with direct paths to the underlying reporting
Corvus Pharmaceuticals' CRVS stock fell 35.7% to $4.74 pre-market today. The decline followed interim data from a Phase 1 trial for soqualitinib. The trial evaluated treatment for moderate to severe atopic dermatitis. Market sentiment was negative ahead of notable financial news. U.S. stock futures, including CRVS, were generally lower this morning.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.